MONTREAL, QUEBEC--(CCNMatthews - April 5, 2006) - Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce the initiation of dosing of its first patient in a Phase I clinical trial of its anticancer product candidate ECO-4601 at the Clinical Research Unit of the Sir Mortimer B. Davis - Jewish General Hospital (JGH), a McGill University Teaching Hospital. The Phase I is designed to test the safety and tolerability of ECO-4601.
